LSU LCMC Health Cancer Center joins the exclusive network of leading cancer institutions utilizing data to improve patient outcomes
Caris Life Sciences, a leading next-generation AI TechBio company and precision medicine pioneer, announced that LSU LCMC Health Cancer Center has joined the Caris Precision Oncology Alliance.
Health Technology Insights: LainaHealth Launches AI-Driven Care Model for Physical Therapy
The Caris POA is a global network of top cancer centers and research groups that work together to advance precision oncology and biomarker-driven research. Members collaborate to set and refine standards for molecular testing through innovative research, aiming to enhance clinical outcomes for cancer patients. Leveraging Caris’ advanced AI bioinformatics and machine learning capabilities, Caris POA members can utilize a vast multi-modal database to drive groundbreaking research and improve patient care.
“We’re thrilled to welcome the LSU LCMC Health Cancer Center to the Caris Precision Oncology Alliance,” said James Hamrick, MD, MPH, Chairman of the Caris POA. “We continue to grow our network alliance with organizations that share our mission to unite research and education to help unburden cancer patients as they navigate their diagnosis.”
The LSU LCMC Health Cancer Center is a multidisciplinary cancer center dedicated to excellence in prevention, early detection, treatment and eradication of cancer in Louisiana and the Gulf South. The Cancer Center’s mission is to reduce the cancer burden through a culture founded in excellence in research, clinical care, education and active partnership that provides high-impact discoveries and increased access to cutting-edge medical care for everyone throughout Louisiana and beyond.
Health Technology Insights: Cottage Health Partners with Clearway Health to Launch Specialty Pharmacy Program
“No two cancers are identical. The future of cancer care is to move away from a “one-size fits all” approach to personalized treatments targeting the unique molecular features of each cancer,” said Dr. Lucio Miele, Director, LSU LCMC Health Cancer Center. “The Precision Oncology Alliance is a worldwide network of leading cancer centers dedicated to discovering new molecular markers to guide cancer therapies and provide access to cutting-edge clinical trials.”
With the newest addition, the Caris POA now consists of 97 cancer centers, academic institutions, research consortia and healthcare systems, including 45 NCI-designated cancer centers, all collaborating to advance precision oncology and biomarker-driven research. Using Caris molecular profiling, which includes comprehensive genomic, transcriptomic, and proteomic data, Caris aims to empower its network to prioritize therapeutic options and identify beneficial clinical trial opportunities for patients. Caris POA members can also participate in an expanding range of biomarker-directed trials sponsored by biopharmaceutical companies. Furthermore, Caris POA institutions have access to one of the industry’s largest and most detailed multi-modal databases, containing matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, with tens of billions of data points per patient.
Health Technology Insights: Weave to Acquire TrueLark, Boosting AI Front Office Automation
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
